Recombinant granulocyte-macrophage colony stimulating factor - Profarma

Drug Profile

Recombinant granulocyte-macrophage colony stimulating factor - Profarma

Alternative Names: PF-11

Latest Information Update: 16 Jun 2015

Price : $50

At a glance

  • Originator Profarma
  • Class Adjuvants; Glycoproteins; Granulocyte-macrophage colony-stimulating factors
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer; Haematological disorders

Most Recent Events

  • 16 Jun 2015 Early research in Haematological disorders in Lithuania (Parenteral) (Profarma pipeline, June 2015)
  • 16 Jun 2015 Early research in Cancer in Lithuania (Parenteral) (Profarma pipeline, June 2015)
  • 02 Apr 2015 Profarma has patent protection for recombinant granulocyte-macrophage colony stimulating factor (Profarma website, June 2015) before April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top